Show simple item record

dc.contributor.authorSchifano, Fabrizio
dc.contributor.authorPapanti, Gabriele Duccio
dc.contributor.authorCorkery, John
dc.contributor.authorOrsolini, Laura
dc.date.accessioned2019-02-21T15:01:54Z
dc.date.available2019-02-21T15:01:54Z
dc.date.issued2018-08-30
dc.identifier.citationSchifano , F , Papanti , G D , Corkery , J & Orsolini , L 2018 , ' Post-traumatic stress and substance misuse; neurobiological and clinical pharmacological correlates ' , Research and Advances in Psychiatry , vol. 5 , no. 2 , pp. 52-60 . < https://www.rapjournal.eu/index.php?PAGE=articolo_dett&ID_ISSUE=1019&id_article=8704 >
dc.identifier.issn2421-3349
dc.identifier.otherPURE: 15003212
dc.identifier.otherPURE UUID: 47b8a373-a727-4996-9ab3-7c14188c5b87
dc.identifier.urihttp://hdl.handle.net/2299/21143
dc.description.abstractIn post-traumatic stress disorder (PTSD) clients, the use of drugs and alcohol may be used as a self-prescribed treatment to both avoid trauma reminders and cope with the related distress. Conversely, substance misuse ‘per se’ might predispose to experience traumatic events. The present study aimed here at presenting an overview of most recent studies covering a range of issues relating to PTSD and substance misuse; namely: substances most frequently ingested by PTSD clients; neurobiological correlates; and treatment/management of these clients. Beyond the alcohol abuse/misuse, drugs most frequently misused are represented by opiates/opioids; sedatives; cannabis; and cocaine. PTSD-related khat misuse issues are here briefly discussed as well. From the neurobiological point of view, issues relating to amygdala and hippocampus dysfunction, with consequent altered levels of fear extinction/memory disruption, have been considered. Furthermore, PTSD may be characterized by imbalance of a range of neurotransmitter pathways, mainly cannabinoid-receptor (CB1); serotonin; and oxytocin. Although there is currently no effective pharmacotherapy for PTSD, most clients may be regularly prescribed with antidepressants; anxiolytics/sedative-hypnotics; and antipsychotics. Due to the heterogeneity of PTSD phenotype, focusing on the symptoms/signs of the PTSD client would allow for more personalized treatment. Although more research is needed, the development of chemoprophylactic treatments, e.g., intervening pharmacologically after trauma to prevent the occurrence of PTSD seems particularly promising.en
dc.format.extent9
dc.language.isoeng
dc.relation.ispartofResearch and Advances in Psychiatry
dc.subjectPTSD
dc.subjectpost-traumatic stress disorder
dc.subjectaddiction
dc.subjectdrug misuse
dc.subjectstress
dc.subjectpharmacotherapy
dc.subjectrecreational drugs
dc.titlePost-traumatic stress and substance misuse; neurobiological and clinical pharmacological correlatesen
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionPsychopharmacology, Drug Misuse and Novel Psychoactive Substances Unit
dc.contributor.institutionDepartment of Pharmacy, Pharmacology and Postgraduate Medicine
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionDepartment of Clinical and Pharmaceutical Sciences
dc.description.statusPeer reviewed
dc.identifier.urlhttps://www.rapjournal.eu/index.php?PAGE=articolo_dett&ID_ISSUE=1019&id_article=8704
rioxxterms.versionAM
rioxxterms.versionVoR
rioxxterms.typeOther
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record